Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Researchers identify key role of microRNAs in melanoma metastasis

12.07.2011
Tumor cell biomarkers show promise as therapeutic targets for deadliest form of skin cancer

Researchers at the NYU Cancer Institute, an NCI-designated cancer center at NYU Langone Medical Center, identified for the first time the key role specific microRNAs (miRNAs) play in melanoma metastasis to simultaneously cause cancer cells to invade and immunosuppress the human body's ability to fight abnormal cells. The new study is published in the July 11, 2011 issue of the journal Cancer Cell.

Researchers performed a miRNA analysis of human melanoma tissues, including primary and metastatic tumors. They found in both sets of tumor cells significantly high levels of a cluster of two miRNAs called miR-30b and miR-30d (miR-30b/30d). Higher levels of miR-30b/30d in melanoma tumor cells were linked to advanced stages of cancer, tumor progression, potential metastasis and reduced overall patient survival.

"Melanoma patients with higher levels of these miRNAs in their tumor cells are at greater risk for melanoma metastasis from their primary tumor," said Eva Hernando, PhD, senior author of the study and assistant professor in the Department of Pathology at NYU Langone Medical Center.

In the study, the benefit of silencing miRNAs in melanoma tumor cells was tested. This experiment led to the successful suppression of cell invasion, migration and metastatic melanoma. In addition, the study shows the over expression of miRNAs in tumor cells suppresses the normal function of GALNT7, an enzyme that modifies proteins on the surface of cells to control cell communication, cell migration and immune system surveillance. These miRNAs inhibit the role of GALNT7 in tumor cells leading to the spread of cancer.

"Our study results may have a direct clinical implication on the management of melanoma patients since these miRNAs can potentially serve as a new biomarker of a more aggressive tumor," said Avital Gaziel-Sovran, lead author of the study and NYU graduate student who conducted many of the experiments.

Melanoma is the deadliest form of skin cancer and one of the most invasive and aggressive tumor types. In the study, miRNAs were identified as strong promoters of the metastatic behavior of melanoma cells. miRNAs are the short pieces of RNA that regulate gene and cellular activities and are known to be linked to cancers like melanoma. However, this new research shows how these miRNAs increase melanoma cells' capacity to migrate, spread and metastasize.

"This study adds another piece to the melanoma puzzle showing how a few millimeter lesion on the skin's surface can quickly metastasize by invading other parts of the body like the lungs and brain so aggressively," said Dr. Hernando, a member of the Melanoma Program at the NYU Cancer Institute and the Center of Excellence on Cancers of the Skin at NYU Langone. "This study helps us better understand exactly why melanoma is so metastatic and suggests how miRNAs are a new potential therapeutic target for battling the disease."

The study was a collaboration between the Departments of Pathology, Dermatology, Environmental Medicine and Medicine, the Interdisciplinary Melanoma Cooperative Group and the NYU Center for Health Informatics and Bioinformatics at NYU Langone Medical Center and the Department of Chemistry at New York University.

About NYU Langone Medical Center:

NYU Langone Medical Center, a world-class, patient-centered, integrated, academic medical center, is one on the nation's premier centers for excellence in clinical care, biomedical research and medical education. Located in the heart of Manhattan, NYU Langone is composed of three hospitals – Tisch Hospital, its flagship acute care facility; the Rusk Institute of Rehabilitation Medicine, the first rehabilitation hospital in the world; and the Hospital for Joint Diseases, one of only five hospitals in the nation dedicated to orthopaedics and rheumatology – plus the NYU School of Medicine, which since 1841 has trained thousand of physicians and scientists who have helped to shape the course of medical history. The medical center's tri-fold mission to serve, teach and discover is achieved 365 days a year through the seamless integration of a culture devoted to excellence in patient care, education and research. For more information, go to www.NYULMC.org.

Lauren Woods | EurekAlert!
Further information:
http://www.nyumc.org

More articles from Life Sciences:

nachricht 'Y' a protein unicorn might matter in glaucoma
23.10.2017 | Georgia Institute of Technology

nachricht Microfluidics probe 'cholesterol' of the oil industry
23.10.2017 | Rice University

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Salmonella as a tumour medication

HZI researchers developed a bacterial strain that can be used in cancer therapy

Salmonellae are dangerous pathogens that enter the body via contaminated food and can cause severe infections. But these bacteria are also known to target...

Im Focus: Neutron star merger directly observed for the first time

University of Maryland researchers contribute to historic detection of gravitational waves and light created by event

On August 17, 2017, at 12:41:04 UTC, scientists made the first direct observation of a merger between two neutron stars--the dense, collapsed cores that remain...

Im Focus: Breaking: the first light from two neutron stars merging

Seven new papers describe the first-ever detection of light from a gravitational wave source. The event, caused by two neutron stars colliding and merging together, was dubbed GW170817 because it sent ripples through space-time that reached Earth on 2017 August 17. Around the world, hundreds of excited astronomers mobilized quickly and were able to observe the event using numerous telescopes, providing a wealth of new data.

Previous detections of gravitational waves have all involved the merger of two black holes, a feat that won the 2017 Nobel Prize in Physics earlier this month....

Im Focus: Smart sensors for efficient processes

Material defects in end products can quickly result in failures in many areas of industry, and have a massive impact on the safe use of their products. This is why, in the field of quality assurance, intelligent, nondestructive sensor systems play a key role. They allow testing components and parts in a rapid and cost-efficient manner without destroying the actual product or changing its surface. Experts from the Fraunhofer IZFP in Saarbrücken will be presenting two exhibits at the Blechexpo in Stuttgart from 7–10 November 2017 that allow fast, reliable, and automated characterization of materials and detection of defects (Hall 5, Booth 5306).

When quality testing uses time-consuming destructive test methods, it can result in enormous costs due to damaging or destroying the products. And given that...

Im Focus: Cold molecules on collision course

Using a new cooling technique MPQ scientists succeed at observing collisions in a dense beam of cold and slow dipolar molecules.

How do chemical reactions proceed at extremely low temperatures? The answer requires the investigation of molecular samples that are cold, dense, and slow at...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

3rd Symposium on Driving Simulation

23.10.2017 | Event News

ASEAN Member States discuss the future role of renewable energy

17.10.2017 | Event News

World Health Summit 2017: International experts set the course for the future of Global Health

10.10.2017 | Event News

 
Latest News

Microfluidics probe 'cholesterol' of the oil industry

23.10.2017 | Life Sciences

Gamma rays will reach beyond the limits of light

23.10.2017 | Physics and Astronomy

The end of pneumonia? New vaccine offers hope

23.10.2017 | Health and Medicine

VideoLinks
B2B-VideoLinks
More VideoLinks >>>